Biallelic inactivation of TP53 was seen in 35% (8/23) of patients (Supplementary Table 3) and was particularly enriched in t(11;14) patients (60%), offering a possible explanation for the adverse outcome observed in this traditionally low-risk primary MM subtype. The gene discussed is TP53; the disease is Miyoshi myopathy.